Fundraising Fox
Genomenon
Ann Arbor, US · Founded 2014 · Delaware corporation · 139 employees on LinkedIn · 8 known investors
Find your way into Genomenon
373 people in our graph can introduce you to the Genomenon team.
Sign up to see every warm intro you have to Genomenon
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Genomenon team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Genomenon uses AI to read biomedical literature and expert scientists to curate variant- and patient-level genomic evidence, delivering regulatory-grade real-world evidence. Its products, including Mastermind and CKB, serve drug development teams and clinical genetic testing labs for variant interpretation and drug program decisions.
Founders & leadership
Genomenon was founded in 2014 by Mark Kiel.
Board
Investors · 8
How we know: Beringea's portfolio page · a partner's Signal profile · funding news · Not right? Tell us
How we know: Green Park & Golf Ventures's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
How we know: IrishAngels's portfolio page · a partner's Signal profile · the VCSheet dataset · Not right? Tell us
How we know: Marram Ventures's portfolio page · Not right? Tell us
How we know: funding news · the VCSheet dataset · Not right? Tell us
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$34.8M disclosed across 5 of 6 rounds · 2015–2026
▶$6MraisedJul 2026 · 30 investors · BiotechnologyRule 506(b)
- Michael KleinExecutive Officer, Director
- Mark KielExecutive Officer, Director
- Patricia GlazaDirector
- David GregorkaDirector
- Michael GrossDirector
- Brian GroarkExecutive Officer
- Sam GlobusExecutive Officer
- Offering amount
- $10M
- Amount sold
- $6M
- First sale
- Jul 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.5MraisedMay 2024 · 30 investors · BiotechnologyRule 506(b)
- Mark KielExecutive Officer, Director
- Patricia GlazaDirector
- Michael KleinExecutive Officer, Director
- David GregorkaDirector
- Michael GrossDirector
- Sam GlobusExecutive Officer
- Sean KearneyExecutive Officer
- Offering amount
- $6M
- Amount sold
- $5.5M
- First sale
- May 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20MraisedMar 2022 · 23 investors · BiotechnologyRule 506(b)
- Michael KleinExecutive Officer, Director
- David GregorkaDirector
- Patricia GlazaDirector
- Michael GrossDirector
- Mark KielExecutive Officer, Director
- Offering amount
- $20M
- Amount sold
- $20M
- First sale
- Feb 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.9MraisedMay 2020 · 36 investors · BiotechnologyRule 506(b)
- Mark KielExecutive Officer, Director
- Michael KleinExecutive Officer, Director
- David GregorkaDirector
- Steve SchwartzExecutive Officer
- Patricia GlazaDirector
- Charles MoretDirector
- Offering amount
- $3M
- Amount sold
- $2.9M
- First sale
- May 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$446KraisedAug 2015 · 11 investors · ComputersRule 506(b)
- Eli SalembierExecutive Officer, Director
- Mark KielExecutive Officer, Director
- Sonya SepahbanDirector
- Offering amount
- $1M
- Amount sold
- $446K
- First sale
- Aug 2015
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as Genomenon.
Frequently asked questions
- What does Genomenon do?
- Genomenon uses AI to read biomedical literature and expert scientists to curate variant- and patient-level genomic evidence, delivering regulatory-grade real-world evidence. Its products, including Mastermind and CKB, serve drug development teams and clinical genetic testing labs for variant interpretation and drug program decisions.
- Who founded Genomenon?
- Genomenon was founded by Mark Kiel in 2014.
- Who are Genomenon's investors?
- Genomenon's investors include Beringea, Green Park & Golf Ventures, ID Ventures, Invest Michigan, IrishAngels, Marram Ventures, Michigan Rise, Spring Mountain Capital.
- How much funding has Genomenon raised?
- Genomenon has disclosed $34.8M raised across 5 of its 6 known rounds.
- Where is Genomenon headquartered?
- Genomenon is headquartered in Ann Arbor, US.